Three drugs for the treatment of stomach and esophageal diseases have their circulation registration certificates revoked

The Drug Administration of Vietnam (Ministry of Health) has just issued a decision to revoke the certificate of drug circulation registration in Vietnam for 5 drugs that have been granted circulation registration certificates.

Specifically, the Drug Administration of Vietnam has revoked the certificate of drug registration in Vietnam for the following products: Pompezo 40mg, Pompezo 20mg, Choludexan 300mg hard capsule and Etacid 0.05% spray suspension. nose.

These four drugs are registered by Minh Ky Pharmaceutical Joint Stock Company (address in Ho Chi Minh City). The drug manufacturing facility is World Medicine Ilac San. on Tic. AS in Turkey.

Among these, Pompezo 40mg and 20mg drugs are indicated for cases of gastroesophageal reflux disease, erosive reflux esophagitis, long-term treatment for patients with healed esophagitis to prevent esophagitis. prevent recurrence…

Choludexan 300mg is indicated for the treatment of primary biliary cirrhosis. And Etacid is used to treat seasonal allergic rhinitis, year-round allergic rhinitis, prevent seasonal allergic rhinitis or treat acute sinusitis.

The fifth drug that has been revoked the certificate of drug registration in Vietnam is Ulsepan 40mg in the form of enteric coated tablets. This drug is registered by DP Altus One Member Co., Ltd., and is indicated for the treatment of gastroesophageal reflux disease, gastrointestinal ulcers …

The Drug Administration of Vietnam requires drug registration and import establishments to coordinate with drug manufacturers to send recall notices to drug wholesalers, retailers, and users, and recall all drugs. For the above-mentioned drug items, send a recall report to the Drug Administration of Vietnam before June 15.

Thanh Hien